Drugs for rare diseases announcement is a step forward for patients
Ottawa, March 22, 2023 – Innovative Medicines Canada (IMC) is encouraged by the federal government’s announcement regarding its intentions for […]
Drugs for Rare Diseases (DRD)
Increasing timely access to medicines for patients suffering from rare diseases.
One in 12 Canadians, two-thirds of them children, suffer from a rare disease. IMC is committed to advocating for policies that increase timely access to medicines and treatments for patients suffering from rare diseases.
Canada desperately needs a rare disease strategy that’ll enable better patient care and access to treatment for those living with rare diseases.
News
The Clock is Ticking for Ottawa to Deliver on Its Rare Disease Strategy
This article originally appeared in Maclean’s print and healthinsights.ca on February 16, 2023 Canada desperately needs a rare disease strategy that’ll enable […]
A National Rare Disease Strategy Could Change Patients’ Lives
Ottawa, February 14, 2023 – With Rare Disease Day fast approaching, the federal government has an opportunity to make a […]
Government Submissions
Addendum to IMC Submission on Drugs for Rare Diseases
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
Towards a Value-based and Pan-Canadian Rare Disease Strategy
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Infographics & Data
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
Analysis & Reports
Sorry, no posts were found. Please check again later.
Newsroom
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
About
Our member companies, which range from fledgling start-ups to established organizations, are revolutionizing healthcare through the discovery and development of […]
